Biologisk behandling av inflammatorisk tarmsykdom ved Aker universitetssykehus : effekt av TNF-alfa-hemmeren adalimumab

The intention of this retrospective study is evaluation of the effect of the TNF á inhibitor adalimumab in patients with inflammatory bowel disease (IBD) treated at Aker University Hospital. The patient data were extracted from electronic patient charts. All patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with at least one injection of adalimumab, were included. A total of 58 patients were included; 51 CD patients and 7 UC patients. In the CD group a reduction of CRP was observed, but this was not significantly altered (p=0,071). In the UC group significant changes of CRP were absent. In the CD group, significant alterations of calprotectin values were first observed after 6 months of treatment (p=0,001). There were no significant alterations of calprotectin values at any time in the UC group. The Harvey Bradshaw Index, used in clinical evaluation of CD, was significantly reduced after 3 weeks of treatment with adalimumab (p